Literature DB >> 23357335

The role of phosphodiesterases in hippocampal synaptic plasticity.

Thomas M Sanderson1, Emanuele Sher.   

Abstract

Phosphodiesterases (PDEs) degrade cyclic nucleotides, signalling molecules that play important roles in synaptic plasticity and memory. Inhibition of PDEs may therefore enhance synaptic plasticity and memory as a result of elevated levels of these signalling molecules, and this has led to interest in PDE inhibitors as cognitive enhancers. The development of new mouse models in which PDE subtypes have been selectively knocked out and increasing selectivity of PDE antagonists means that this field is currently expanding. Roles for PDE2, 4, 5 and 9 in synaptic plasticity have so far been demonstrated and we review these studies here in the context of cyclic nucleotide signalling more generally. The role of other PDE families in synaptic plasticity has not yet been investigated, and this area promises to advance our understanding of cyclic nucleotide signalling in synaptic plasticity in the future. This article is part of the Special Issue entitled 'Glutamate Receptor-Dependent Synaptic Plasticity'.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cyclic nucleotides; Depotentiation; Hippocampus; LTD; LTP; Phosphodiesterases; Synaptic plasticity; cAMP; cGMP

Mesh:

Substances:

Year:  2013        PMID: 23357335     DOI: 10.1016/j.neuropharm.2013.01.011

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  17 in total

1.  Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors.

Authors:  Frederik J R Rombouts; Gary Tresadern; Peter Buijnsters; Xavier Langlois; Fulgencio Tovar; Thomas B Steinbrecher; Greet Vanhoof; Marijke Somers; José-Ignacio Andrés; Andrés A Trabanco
Journal:  ACS Med Chem Lett       Date:  2015-01-15       Impact factor: 4.345

2.  Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory.

Authors:  Robbert Havekes; Alan J Park; Rosa E Tolentino; Vibeke M Bruinenberg; Jennifer C Tudor; Yool Lee; Rolf T Hansen; Leonardo A Guercio; Edward Linton; Susana R Neves-Zaph; Peter Meerlo; George S Baillie; Miles D Houslay; Ted Abel
Journal:  J Neurosci       Date:  2016-08-24       Impact factor: 6.167

Review 3.  PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment.

Authors:  Shuichi Yanai; Shogo Endo
Journal:  Mol Neurobiol       Date:  2018-10-11       Impact factor: 5.590

Review 4.  Phosphodiesterase regulation of alcohol drinking in rodents.

Authors:  Marian L Logrip
Journal:  Alcohol       Date:  2015-05-29       Impact factor: 2.405

5.  Alteration of Neuronal Excitability and Short-Term Synaptic Plasticity in the Prefrontal Cortex of a Mouse Model of Mental Illness.

Authors:  Gregg W Crabtree; Ziyi Sun; Mirna Kvajo; Jantine A C Broek; Karine Fénelon; Heather McKellar; Lan Xiao; Bin Xu; Sabine Bahn; James M O'Donnell; Joseph A Gogos
Journal:  J Neurosci       Date:  2017-03-10       Impact factor: 6.167

6.  The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases.

Authors:  Susana S Correia; Rajesh R Iyengar; Peter Germano; Kim Tang; Sylvie G Bernier; Chad D Schwartzkopf; Jenny Tobin; Thomas W-H Lee; Guang Liu; Sarah Jacobson; Andrew Carvalho; Glen R Rennie; Joon Jung; Paul A Renhowe; Elisabeth Lonie; Christopher J Winrow; John R Hadcock; Juli E Jones; Mark G Currie
Journal:  Front Pharmacol       Date:  2021-05-24       Impact factor: 5.810

7.  Efficacy of selective PDE4D negative allosteric modulators in the object retrieval task in female cynomolgus monkeys (Macaca fascicularis).

Authors:  Jane S Sutcliffe; Vahri Beaumont; James M Watson; Chang Sing Chew; Maria Beconi; Daniel M Hutcheson; Celia Dominguez; Ignacio Munoz-Sanjuan
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

Review 8.  Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.

Authors:  Katheleen J Gardiner
Journal:  Drug Des Devel Ther       Date:  2014-12-17       Impact factor: 4.162

9.  Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease.

Authors:  Roberta Ricciarelli; Chiara Brullo; Jos Prickaerts; Ottavio Arancio; Carla Villa; Claudia Rebosio; Elisa Calcagno; Matilde Balbi; Britt T J van Hagen; Elentina K Argyrousi; Hong Zhang; Maria Adelaide Pronzato; Olga Bruno; Ernesto Fedele
Journal:  Sci Rep       Date:  2017-04-12       Impact factor: 4.379

10.  Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats.

Authors:  Bart de Laat; Yvonne E Kling; Gwen Schroyen; Maarten Ooms; Jacob M Hooker; Guy Bormans; Koen Van Laere; Jenny Ceccarini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.